Source: DGNews | Posted 9 years ago
Neurology Study Finds Approved Dose of Avonex (Interferon Beta-1a) Equally Effective as Higher Dose in Treating Relapsing Multiple Sclerosis
Tags:
CAMBRIDGE, MA -- November 26, 2002 -- Biogen, Inc. (Nasdaq: BGEN) Data published in the November 26, 2002 issue of the journal Neurology determine that the commercially available dose of Biogen, Inc.'s multiple sclerosis therapy Avonex
Comments